SG10201900323SA - Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells - Google Patents

Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Info

Publication number
SG10201900323SA
SG10201900323SA SG10201900323SA SG10201900323SA SG10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA
Authority
SG
Singapore
Prior art keywords
cell
cells
based immunotherapy
inducing
pluripotent stem
Prior art date
Application number
SG10201900323SA
Inventor
Shin Kaneko
Hiroshi Kawamoto
Kyoko Masuda
Atsutaka Minagawa
Akitsu Hotta
Yutaka Shimazu
Hiroshi Ichise
Original Assignee
Univ Kyoto
Thyas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto, Thyas Co Ltd filed Critical Univ Kyoto
Publication of SG10201900323SA publication Critical patent/SG10201900323SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METHODFOR INDUCING T CELLS FOR CELL-BASED IMMUNOTHERAPY FROM PLURIPOTENT STEM CELLS OF DISCLOSURE Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of: () providing Rag 1 and/or Rag2 gene knockout human pluripotent stem cells bearing genes encoding a T cell receptor specific for a desired antigen, and (2) inducing T cells from the pluripotent stem cells of step (1). Further provided are a cell-based immunotherapy method that uses the T cells for the cell-based immunotherapy and an iPS cell bank for the cell-based immunotherapy. Figure for publication: None 66
SG10201900323SA 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells SG10201900323SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026341P 2014-07-18 2014-07-18
US201462026332P 2014-07-18 2014-07-18

Publications (1)

Publication Number Publication Date
SG10201900323SA true SG10201900323SA (en) 2019-02-27

Family

ID=55078633

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900323SA SG10201900323SA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
SG11201701191WA SG11201701191WA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701191WA SG11201701191WA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Country Status (9)

Country Link
US (1) US20170369850A1 (en)
EP (1) EP3170897B1 (en)
JP (3) JP6715482B2 (en)
KR (1) KR102654784B1 (en)
CN (2) CN107075484B (en)
AU (1) AU2015290554A1 (en)
IL (1) IL250132A0 (en)
SG (2) SG10201900323SA (en)
WO (1) WO2016010148A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536718B (en) 2014-05-21 2021-04-27 国立大学法人京都大学 Method for producing pancreatic islet cells and therapeutic agent for pancreatic disease containing pancreatic islet cells
WO2017159088A1 (en) * 2016-03-16 2017-09-21 国立大学法人京都大学 Method for preparing cultured cells or cultured tissue for transplantation
JP2019080491A (en) * 2016-03-16 2019-05-30 国立大学法人京都大学 Method for inducing NY-ESO1 antigen-specific T cells for immune cell therapy
HUE056387T2 (en) * 2016-04-15 2022-02-28 Univ Kyoto Method for inducing antigen specific cd8 positive t cells
WO2018007976A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP7131775B2 (en) * 2017-02-06 2022-09-06 国立研究開発法人国立がん研究センター novel T-cell receptor
KR102486691B1 (en) * 2018-01-31 2023-01-11 고려대학교 산학협력단 Human Induced Pluripotent Stem Cell Lines Reflecting Highly Polymorphic CYP Genotypes in Korean
JPWO2020251046A1 (en) * 2019-06-14 2020-12-17
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs
WO2021157685A1 (en) * 2020-02-07 2021-08-12 学校法人順天堂 Cytotoxic t cells derived from human t cell-derived ips cells
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2023553419A (en) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド Genetically engineered cells and their uses
WO2022145490A1 (en) * 2021-01-04 2022-07-07 サイアス株式会社 Method for producing regenerated t cell via ips cell
EP4320224A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
CN117479952A (en) 2021-04-07 2024-01-30 世纪治疗股份有限公司 Combined artificial cell death/reporter polypeptides for chimeric antigen receptor cells and uses thereof
AU2022253891A1 (en) 2021-04-07 2023-08-24 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
IL307358A (en) 2021-04-07 2023-11-01 Century Therapeutics Inc Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
AU2022259170A1 (en) * 2021-04-16 2023-10-12 Thyas Co. Ltd. Cell bank composed of ips cells for introducing t cell receptor gene
CN113388612A (en) * 2021-06-18 2021-09-14 重庆天科雅生物科技有限公司 Primer designed for TCR with epitope point of IYVLVMLVL and application thereof
AU2022423987A1 (en) 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
WO2023215826A1 (en) 2022-05-04 2023-11-09 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891209A1 (en) * 2005-06-06 2008-02-27 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for generating a t cell against an antigen of interest.
CA2715305A1 (en) * 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating t cells
KR101811235B1 (en) * 2009-06-05 2017-12-21 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Reprogramming T cells and hematopoietic cells
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
EP2853590B1 (en) * 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
US20170128556A1 (en) * 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes

Also Published As

Publication number Publication date
WO2016010148A1 (en) 2016-01-21
US20170369850A1 (en) 2017-12-28
KR102654784B1 (en) 2024-04-04
JP2022101655A (en) 2022-07-06
CN114292817A (en) 2022-04-08
SG11201701191WA (en) 2017-03-30
EP3170897B1 (en) 2020-05-13
CN107075484A (en) 2017-08-18
AU2015290554A1 (en) 2017-03-09
CN107075484B (en) 2022-01-28
EP3170897A1 (en) 2017-05-24
JP6715482B2 (en) 2020-07-01
IL250132A0 (en) 2017-03-30
KR20170042601A (en) 2017-04-19
JP2020141695A (en) 2020-09-10
EP3170897A4 (en) 2018-03-07
JPWO2016010148A1 (en) 2017-06-15
JP7440027B2 (en) 2024-02-28
JP7072808B2 (en) 2022-05-23

Similar Documents

Publication Publication Date Title
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
ZA202310779B (en) Compositions and methods for enhanced gene expression
MX2021008143A (en) Methods for harvesting mammalian cell cultures.
IL249828A0 (en) Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
MY189778A (en) Method for producing retinal pigment epithelial cells
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
IL248451A0 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MX2015015406A (en) Arrays of discrete cell culture microenvironments, methods of making such arrays and uses thereof.
TW201612312A (en) Meristematic plant cells and method of isolating them
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
SG10201903910RA (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
EP3369809A4 (en) Method for obtaining leydig cells by carrying out induced differentiation on human induced pluripotent stem cells, and use of leydig cells
CY1122993T1 (en) PRODUCTION METHOD FOR PLRIPOTENTIAL STEM CELLS HAVING AN ANTIGEN-SPECIFIC T CELL RECEPTOR GENE
EP3170895A4 (en) Production method for pluripotent stem cells having antigen-specific t cell receptor gene
EP3702444A4 (en) Method for inducing differentiation of pluripotent stem cells into hepatocytes
MX2021001981A (en) Methods of preparing a poloxamer for use in cell culture medium.
GB201608060D0 (en) Method of culturing T cells
EP3162812A4 (en) Mutant hemagglutinin complex protein, and method for culturing pluripotent stem cells using same
MX2019001946A (en) Marker for neural stem cells.
IL281231A (en) Methods of continuous cell culture
EP3194573A4 (en) Mammalian pluripotent stem cells, methods for their production, and uses thereof
EP3587560A4 (en) Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
SG10201912931RA (en) Pluripotent stem cell manufacturing system, method for inducing stem cells, floating culture method for stem cells, floating culture vessel for stem cells, method for producing induced pluripotent stem cells, and method for producing particular somatic cells from animal cells
EP3336178A4 (en) Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for cell culturing